The Hemophagocytic Syndrome in an Immunocompromised Patient: A Diagnostic Challenge

Autor: I Fiteni, G Perez-Lungmus, JM Grasa, C Motis

Publikováno v: Canadian Journal of Infectious Diseases, Vol 15, Iss 2, Pp 101-103 (2004)

Externí odkaz: https://doaj.org/article/e6ce6a8536204c868a65a0d3ff9d9243

The Hemophagocytic Syndrome in an Immunocompromised Patient: A Diagnostic Challenge

Autor: C Motis, JM Grasa, G Perez-Lungmus, I Fiteni

Publikováno v: Canadian Journal of Infectious Diseases, Vol 15, Iss 2, Pp 101-103 (2004)

1Department of Internal Medicine, Clinica Montpellier; 2Haematology consultant, Clinica Montpellier; 3Laboratorio Jose Maria Grasa Biel, Sociedad Anonima; 4Department of Neurology, Clinica Montpellier, Zaragoza, Spain Correspondence: Dr Isabel Fiteni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400553b62bcd03eee868162fd86bff42
https://doi.org/10.1155/2004/325836

[Acquired and inherited hypercoagulability among patients with cerebral venous thrombosis]

Autor: Sánchez-Martín B, Jm, Grasa, Latorre A, Ma, Montañés, José Antonio García-Erce, Torres M, Mt, Calvo, Giralt M

Publikováno v: Europe PubMed Central

Cerebral venous thrombosis (CVT) is considered to be a relative unusual pathology, probably underdiagnosed. Many acquired and inherited hypercoagulability states (HS) have been described as cause of CVT.[corrected] We evaluated the incidence of acqui

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a4020cba3bb6f0d3c38c840023fc500a
http://europepmc.org/abstract/med/12396970

Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.

Autor: Andrade-Campos MM; Translational Research Unit, Aragon Health Research Institute (IIS-A), Zaragoza, Spain.; CIBER de Enfermedades Raras, CIBERER, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain.; Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain., Liévano P; Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain., Espinosa-Lara N; Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain., Soro-Alcubierre G; Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain., Grasa-Ulrich JM; Department of Hematology, Miguel Servet University Hospital, Zaragoza, Spain., López-Gómez L; Department of Hematology, Royo Villanova Hospital, Zaragoza, Spain., Baringo T; Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain., Giraldo P; Translational Research Unit, Aragon Health Research Institute (IIS-A), Zaragoza, Spain.; CIBER de Enfermedades Raras, CIBERER, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain.

Publikováno v: European journal of haematology [Eur J Haematol] 2016 Dec; Vol. 97 (6), pp. 576-582. Date of Electronic Publication: 2016 May 30.

RIT with Y90-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution.

Autor: Andrade Campos MM; Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain., Montes Limón AE, Grasa JM, Lievano P, Baringo T, Giraldo P

Publikováno v: Journal of oncology [J Oncol] 2012; Vol. 2012, pp. 412742. Date of Electronic Publication: 2012 Sep 25.